# A Trial of Brexpiprazole in the Treatment of Borderline Personality Disorder

> **NCT04100096** · PHASE2 · COMPLETED · sponsor: **Otsuka Pharmaceutical Development & Commercialization, Inc.** · enrollment: 332 (actual)

## Conditions studied

- Borderline Personality Disorder

## Interventions

- **DRUG:** Brexpiprazole
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04100096
- **Lead sponsor:** Otsuka Pharmaceutical Development & Commercialization, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-17
- **Primary completion:** 2021-06-27
- **Final completion:** 2021-06-27
- **Target enrollment:** 332 (ACTUAL)
- **Last updated:** 2024-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04100096

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04100096, "A Trial of Brexpiprazole in the Treatment of Borderline Personality Disorder". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04100096. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*